A large body of in vivo and in vitro researchdemonstrated that Met and DSF-Cu could increase thepotency of chemotherapeutic agents and radiotherapywhen added to the therapeutic regimen as the additionof these two drugs are capable of elevating the levelsof BAX, P53, CASPASE-3, as well as decreasing thelevel of BCL-2 in some types of malignancies suchas pancreas, lung, and breast cancers (30-32). This evidence concerns the gene BCL2 and breast cancer.